132 related articles for article (PubMed ID: 17999663)
21. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.
Riccioni G; Vitulano N; D'Orazio N; Bellocci F
Adv Ther; 2009 Jul; 26(7):700-10. PubMed ID: 19649581
[TBL] [Abstract][Full Text] [Related]
22. Aliskiren/hydrochlorothiazide (Tekturna HCT) for hypertension.
Med Lett Drugs Ther; 2008 Aug; 50(1293):65-6. PubMed ID: 18719523
[No Abstract] [Full Text] [Related]
23. Aliskiren: renin inhibitor for hypertension management.
Cheng JW
Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
[TBL] [Abstract][Full Text] [Related]
24. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren.
Ménard J; Azizi M
J Hypertens; 2007 Sep; 25(9):1775-82. PubMed ID: 17762637
[No Abstract] [Full Text] [Related]
25. Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling.
Lindsay KB; Skrydstrup T
J Org Chem; 2006 Jun; 71(13):4766-77. PubMed ID: 16776501
[TBL] [Abstract][Full Text] [Related]
26. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
27. Conformational analysis of aliskiren, a potent renin inhibitor, using high-resolution nuclear magnetic resonance and molecular dynamics simulations.
Matsoukas MT; Zoumpoulakis P; Tselios T
J Chem Inf Model; 2011 Sep; 51(9):2386-97. PubMed ID: 21777001
[TBL] [Abstract][Full Text] [Related]
28. The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.
Yamaguchi Y; Menear K; Cohen NC; Mah R; Cumin F; Schnell C; Wood JM; Maibaum J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4863-7. PubMed ID: 19615901
[TBL] [Abstract][Full Text] [Related]
29. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
30. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
Sever PS; Gradman AH; Azizi M
J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
[TBL] [Abstract][Full Text] [Related]
31. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
[TBL] [Abstract][Full Text] [Related]
34. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
[TBL] [Abstract][Full Text] [Related]
35. Aliskiren for hypertension: just another option or something truly unique?
Lee S
S D Med; 2007 Oct; 60(10):405-6. PubMed ID: 18019776
[No Abstract] [Full Text] [Related]
36. [Is there a need for direct renin inhibitors?].
Grossman E
Harefuah; 2008 Mar; 147(3):216-7, 278. PubMed ID: 18488862
[TBL] [Abstract][Full Text] [Related]
37. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program.
Lee HY; Oh BH
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):251-7. PubMed ID: 19296761
[TBL] [Abstract][Full Text] [Related]
38. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
[TBL] [Abstract][Full Text] [Related]
39. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
40. Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.
Chen A; Bayly C; Bezençon O; Richard-Bildstein S; Dubé D; Dubé L; Gagné S; Gallant M; Gaudreault M; Grimm E; Houle R; Lacombe P; Laliberté S; Lévesque JF; Liu S; MacDonald D; Mackay B; Martin D; McKay D; Powell D; Remen L; Soisson S; Toulmond S
Bioorg Med Chem Lett; 2010 Apr; 20(7):2204-9. PubMed ID: 20206513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
